Abstract
The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors’ part as these grants did not support the research in this publication.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2295-2296 |
| Number of pages | 2 |
| Journal | Haematologica |
| Volume | 106 |
| Issue number | 8 |
| DOIs |
|
| State | Published - Aug 2021 |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Erratum: Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: A study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research (Haematologica (2020) 105:5 (1329-1338) DOI: 10.3324/haematol.2019.220756)'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Haematologica, Vol. 106, No. 8, 08.2021, p. 2295-2296.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Erratum
T2 - Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: A study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research (Haematologica (2020) 105:5 (1329-1338) DOI: 10.3324/haematol.2019.220756)
AU - Acute Leukemia Committee of the CIBMTR
AU - Lazaryan, Aleksandr
AU - Dolan, Michelle
AU - Zhang, Mei Jie
AU - Wang, Hai Lin
AU - Kharfan-Dabaja, Mohamed A.
AU - Marks, David I.
AU - Bejanyan, Nelli
AU - Copelan, Edward
AU - Majhail, Navneet S.
AU - Waller, Edmund K.
AU - Chao, Nelson
AU - Prestidge, Tim
AU - Nishihori, Taiga
AU - Kebriaei, Partow
AU - Inamoto, Yoshihiro
AU - Hamilton, Betty
AU - Hashmi, Shahrukh K.
AU - Kamble, Rammurti T.
AU - Bacher, Ulrike
AU - Hildebrandt, Gerhard C.
AU - Stiff, Patrick J.
AU - McGuirk, Joseph
AU - Aldoss, Ibrahim
AU - Beitinjaneh, Amer M.
AU - Muffly, Lori
AU - Vij, Ravi
AU - Olsson, Richard F.
AU - Byrne, Michael
AU - Schultz, Kirk R.
AU - Aljurf, Mahmoud
AU - Seftel, Matthew
AU - Savoie, Mary Lynn
AU - Savani, Bipin N.
AU - Verdonck, Leo F.
AU - Cairo, Mitchell S.
AU - Hossain, Nasheed
AU - Bhatt, Vijaya Raj
AU - Frangoul, Haydar A.
AU - Abdel-Azim, Hisham
AU - Al Malki, Monzr
AU - Munker, Reinhold
AU - Rizzieri, David
AU - Khera, Nandita
AU - Nakamura, Ryotaro
AU - Ringdén, Olle
AU - Van Der Poel, Marjolein
AU - Murthy, Hemant S.
AU - Liu, Hongtao
AU - Mori, Shahram
AU - De Oliveira, Satiro
N1 - Funding Information: The CIBMTR is supported primarily by a public health service grant/cooperative agreement U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); grant/cooperative agreement U24HL138660 from the NHLBI and NCI; grants R21HL140314 and U01HL128568 from the NHLBI; a contract HHSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); grants N00014-18-1-2888 and N00014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; *Anthem, Inc.; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; Boston Children’s Hospital; *Bristol Myers Squibb Co.; *Celgene Corp.; Children’s Hospital of Los Angeles; *Chimerix, Inc.; *CSL Behring; *CytoSen Therapeutics, Inc.; Dana Farber Cancer Institute; *Daiichi Sankyo Co., Ltd.; Fred Hutchinson Cancer Research Center; *Gamida-Cell, Ltd.; Gilead Sciences, Inc.; *GlaxoSmithKline (GSK); HistoGenetics, Inc.; Immucor; Incyte Corporation; Janssen Biotech, Inc.; *Janssen Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite, a Gilead Company; *Magenta Therapeutics; Medac GmbH; The Medical College of Wisconsin; Mediware; Merck & Company, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Oncology; Novartis Pharmaceuticals Corporation; *Omeros Corporation; *Oncoimmune, Inc.; PCORI; *Pfizer, Inc.; *Phamacyclics, LLC; PIRCHE AG; *Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; *Sanofi Genzyme; *Seattle Genetics; *Shire; Sobi, Inc.; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; Swedish Orphan Biovitrum, Inc.; *Takeda Oncology; University of Minnesota; University of Pittsburgh; University of Texas-MD Anderson; University of Wisconsin – Madison and Viracor Eurofins. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members. Funding Information: The CIBMTR is supported primarily by a public health service grant/cooperative agreement U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); grant/cooperative agreement U24HL138660 from the NHLBI and NCI; grant U24CA233032 from the NCI; grants OT3HL147741, R21HL140314 and U01HL128568 from the NHLBI; a contract HHSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); grants N00014-18-1-2888 and N00014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; *Anthem, Inc.; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; Boston Children’s Hospital; *Bristol Myers Squibb Co.; *Celgene Corp.; Children’s Hospital of Los Angeles; *Chimerix, Inc.; *CSL Behring; *CytoSen Therapeutics, Inc.; Dana Farber Cancer Institute; *Daiichi Sankyo Co., Ltd.; Fred Hutchinson Cancer Research Center; *Gamida-Cell, Ltd.; Gilead Sciences, Inc.; *GlaxoSmithKline (GSK); HistoGenetics, Inc.; Immucor; Incyte Corporation; Janssen Biotech, Inc.; *Janssen Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite, a Gilead Company; *Magenta Therapeutics; Medac GmbH; The Medical College of Wisconsin; Mediware; Merck & Company, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Oncology; Novartis Pharmaceuticals Corporation; *Omeros Corporation; *Oncoimmune, Inc.; PCORI; *Pfizer, Inc.; *Phamacyclics, LLC; PIRCHE AG; *Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; *Sanofi Genzyme; *Seattle Genetics; *Shire; Sobi, Inc.; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; Swedish Orphan Biovitrum, Inc.; *Takeda Oncology; University of Minnesota; University of Pittsburgh; University of Texas-MD Anderson; University of Wisconsin – Madison and Viracor Eurofins. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members. Publisher Copyright: © 2021 Ferrata Storti Foundation.
PY - 2021/8
Y1 - 2021/8
N2 - The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors’ part as these grants did not support the research in this publication.
AB - The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors’ part as these grants did not support the research in this publication.
UR - http://www.scopus.com/inward/record.url?scp=85112132769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112132769&partnerID=8YFLogxK
U2 - 10.3324/haematol.2021.279046
DO - 10.3324/haematol.2021.279046
M3 - Comment/debate
C2 - 34333962
AN - SCOPUS:85112132769
SN - 0390-6078
VL - 106
SP - 2295
EP - 2296
JO - Haematologica
JF - Haematologica
IS - 8
ER -